Galectin is a clinical development stage biopharmaceutical company based in Norcross, Georgia, that is targeting fibrotic diseases and cancer with novel galectin inhibitor compounds. Galectins are a class of proteins made by many cells in the body and are important therapeutic targets because they are the mediators of fundamental biologic mechanisms in pathological processes. Galectin Therapeutics leverages its extensive scientific knowledge of galectins to advance their discovery program including research and discovery of new compounds. Through a relationship with a world class research program at the University of Georgia, the Company focuses on the discovery of new carbohydrate molecules that can be used in the therapy of diseases where galectin proteins play a major role including cancer and inflammatory and fibrotic disorders.
Quote | Galectin Therapeutics Inc. (NASDAQ:GALT)
Last: | $2.72 |
---|---|
Change Percent: | 0.0% |
Open: | $2.72 |
Close: | $2.72 |
High: | $2.82 |
Low: | $2.7 |
Volume: | 91,911 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
News | Galectin Therapeutics Inc. (NASDAQ:GALT)
Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) NAVIGATE trial remains on track for interim top-lin...
NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be attending and presenting at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference. Detai...
Message Board Posts | Galectin Therapeutics Inc. (NASDAQ:GALT)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $GALT News Article - Galectin Therapeutics Reports 2022 Financial Results and Provides | whytestocks | investorshangout | 03/30/2023 5:50:47 PM |
Pretty quiet board for a stock that is | vein | investorshub | 03/03/2023 10:30:47 PM |
whytestocks: $GALT News Article - Galectin Therapeutics Provides Final Randomization Status of NAVIG | whytestocks | investorshangout | 03/02/2023 4:30:50 PM |
Another interview : https://www.proactiveinvestors.com/companies/news/1005615/b | Retire43 | investorshub | 02/09/2023 7:21:53 PM |
WTch this interview about Galectin inhibitors! https://www.dropbox.com/s/l1d2v2 | Retire43 | investorshub | 02/09/2023 6:27:11 PM |
News, Short Squeeze, Breakout and More Instantly...
Galectin Therapeutics Inc. Company Name:
GALT Stock Symbol:
NASDAQ Market:
Galectin Therapeutics Inc. Website:
Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) NAVIGATE trial remains on track for interim top-lin...
NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target gale...
NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be attending and presenting at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference. Detai...